乾癬性関節炎患者におけるトファシチニブ治療の有効性、安全性、継続率の性差: フェーズ3および長期延長試験の事後解析
RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718
Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.